Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Colchicine reduces the risk of COVID-19-related complications
Montreal Heart InstituteJanuary 23, 2021 GMT
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, c
Article content
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug tha
Sophie Desmarais vend son condo 11M$ journaldemontreal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journaldemontreal.com Daily Mail and Mail on Sunday newspapers.
National Institute of Allergy and Infectious Diseases, NIH
A press release from a Canadian research group raised hopes that treating people recently diagnosed with Covid-19 with colchicine, a drug commonly used to treat gout, could reduce the risk they will need to be hospitalized.
But outside experts said the data provided were too limited to draw conclusions, leading to discussions of the risks of conducting science via press release, instead of in more detailed manuscripts in peer-reviewed journals. All hoped that colchicine, a cheap and globally available generic medicine with manageable side effects, would prove to be beneficial.
“I’m not, ‘Oh, I don’t buy it’,” said Ashish Jha, dean of the Brown University School of Public Health. “It’s possible. There’s enough plausibility here. This could be a real finding, and if it is that would be great. But this press release doesn’t get us there.”